cIAP-1/HIAP-2 Antibody (681724)

CTS013). Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm of epithelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." > CTS013). Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm of epithelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." title="cIAP-1/HIAP-2 was detected in immersion fixed paraffin-embedded sections of human prostate using Mouse Anti-Human cIAP-1/HIAP-2 Monoclonal Antibody (Catalog # MAB8181) at 15 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm of epithelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." />

cIAP-1/HIAP-2 was detected in immersion fixed paraffin-embedded sections of human prostate using Mouse Anti-Human cIAP-1/HIAP-2 Monoclonal Antibody (Catalog # MAB8181) at 15 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # <a class=

Dual IAP-targeting ASOs knockdown BIRC6, cIAP1 or survivin proteins and lead to marked suppression of CRPC cell proliferation(A-B) Western blotting showing protein levels of BIRC6, cIAP1 and survivin in two CRPC cell lines (A) PC-3 cells and (B) C4-2 cells transfected with Mock or increasing dosages of scrambled ASO (Scrb), dASOs 6w2 and 6w5 for 72 hr. (C) Comparison of dual IAP targeting and single IAP-targeting. Cell viability of PC-3 cells transfected with dASOs 6w2, 6w5 and siRNA-targeting BIRC6, cIAP1 or survivin, was determined by MTS assay at 72 hr after transfection. Cell viabilities of ASO- and siRNA-treated cells were normalized with corresponding Scrb ASO and siRNA controls. Error bars represent mean percentage cell viability ± S.D. Western blotting of 3 IAPs showing comparable amounts of reduced protein expression obtained with dASO and siRNA single IAP-targeting. (D) Proliferation of PC-3 cells transfected with mock, Scrb ASO, dASOs 6w2 and 6w5. Error bars represent mean cell number ± S.D. (E) MTS viability assay of C4-2 cells treated with dASOs. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071009), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: IHC
• Clone: 681724
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

cIAP-1/HIAP-2 Antibody (681724) Summary

• Immunogen: E. coli-derived recombinant human cIAP-1/HIAP-2
  His2-Ser618
  Accession # Q13490
• Specificity: Detects human cIAP-1/HIAP-2 in direct ELISAs. In direct ELISAs, 25% cross-reactivity with recombinant human cIAP-2 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: BIRC2
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 8-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.5 mg/mL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for cIAP-1/HIAP-2 Antibody (681724)

• API1Hiap-2
• apoptosis inhibitor 1
• baculoviral IAP repeat containing 2
• baculoviral IAP repeat-containing 2
• baculoviral IAP repeat-containing protein 2
• BIRC2
• cIAP1
• c-IAP1
• cIAP-1
• hIAP2
• HIAP-2
• IAP homolog B
• IAP2
• IAP-2
• Inhibitor of apoptosis protein 2
• MIHB
• MIHBHIAP2
• NFR2-TRAF signalling complex protein
• RING finger protein 48
• RNF48hiap-2
• TNFR2-TRAF-signaling complex protein 2

Background

cIAP-1 (also known as BIR2, MIHB and HIAP-2) is a member of the inhibitor of apoptosis (IAP) family of proteins that inhibit the proteolytic activity of mature caspases. cIAP-1 has 3 BIR (baculovirus inhibitor of apoptosis) domains, a RING finger domain, and a caspase recruitment domain (CARD). cIAP-1 inhibits caspases by interaction of the BIR domain with the active caspase. Caspase activity may be restored through interactions with the Reaper like motif on mitochondrial proteins such as SMAC/Diablo or HTRA-2/Omi. cIAP-1 is reported to be cleaved by caspases in fetal rat hepatocytes treated with TGF-beta .

1. Roy, N. et al. (1997) EMBO J. 23:6914.
2. Deveraux, Q. et al. (1997) Nature 388:300.
3. Deveraux, Q. and J. Reed (1999) Genes & Develop. 13:239.
4. Herrera, B. et al. (2002) FEBS Letters 520:93.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for cIAP-1/HIAP-2 Antibody (MAB8181)(1)

Publication using MAB8181

• Luk Sze Ue Iris, Xue Hui, Cheng Hongwei et al. The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. Oncotarget. 8/30/2014 [PMID: 25071009]

Bioinformatics

• Gene Symbol: BIRC2
• Uniprot:
  • Q13490()